Leerink Partners analyst Faisal Khurshid has maintained their neutral stance on GLPG stock, giving a Hold rating on December 23.Stay Ahead of ...

Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Galapagos (GLPG – Research Report) today and set a price target ...

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...

Galapagos plans to split into two entities by mid-2025, focusing its core business on cell therapies while spinning off a new ...

Belgian biotech Galapagos (NASDAQ:GLPG) announced a major restructuring drive on Wednesday, with plans to amend its 10-year ...

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain ...

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain ...

CET; Galapagos NV. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In addition, Galapagos ...

Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

Check the time stamp on this data. Updated AI-Generated Signals for Galapagos Nv (GLPG) available here: GLPG. Type a few ...